RPG Life Sciences Limited, engaged in the manufacturing and marketing of pharmaceutical products, posted its Q4 and Full-year results. For full-year, revenue grew from Rs375.57cr to Rs389.14cr, and Profit Before Tax (PBT) grew from Rs36.45cr to Rs53.58cr over last year. EBITDA margin also improved from 15.9% in FY20 to 18.2% in FY21, maintaining its upward trajectory. Q4 revenue was also up from Rs88.67cr to Rs92.76cr and PBT up from Rs3.14cr to Rs8.95cr versus last year.
“In FY21, the overall performance of the company continued to be strong, despite impact of extended Covid‐19 pandemic. On full year basis, revenues and PBT grew by 4% and 47% respectively. EBITDA margin retained its upward trajectory growing from 15.9% to 18.2%,” Yugal Sikri, Managing Director, RPG Life Sciences Ltd., said.
“We continue to be focused on executing our turnaround strategy. It comprises of five initiatives viz. Product portfolio rejuvenation by building chronic and specialty portfolio with new launches; Building our strategic brand assets through life cycle management by introducing line extensions; Deepening our customer coverage in targeted therapies by expanding our field force and deploying digital; Augmenting sales force effectiveness by competencies building initiatives and Improving profitability by opex control, efficient manufacturing operations and sales hygiene,” Sikri added.
At around 12.49 pm, RPG Life Sciences Ltd was trading at Rs473.65 per piece down Rs7.75 or 1.61% from its previous closing of Rs481.40 per piece on the BSE.
#RPG #Life #Sciences #revenue #rises #Rs93cr
( With inputs from indiainfoline)